JP2018527372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018527372A5 JP2018527372A5 JP2018513780A JP2018513780A JP2018527372A5 JP 2018527372 A5 JP2018527372 A5 JP 2018527372A5 JP 2018513780 A JP2018513780 A JP 2018513780A JP 2018513780 A JP2018513780 A JP 2018513780A JP 2018527372 A5 JP2018527372 A5 JP 2018527372A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- compound
- alkoxy
- compound according
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 54
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- -1 hydroxy, carboxy Chemical group 0.000 claims description 16
- 150000002431 hydrogen Chemical class 0.000 claims description 15
- 125000002252 acyl group Chemical group 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 125000003282 alkyl amino group Chemical group 0.000 claims description 12
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 125000001475 halogen functional group Chemical group 0.000 claims description 9
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000000732 arylene group Chemical group 0.000 claims description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 210000004556 brain Anatomy 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000000277 Splenic Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000002471 spleen cancer Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562219380P | 2015-09-16 | 2015-09-16 | |
| US62/219,380 | 2015-09-16 | ||
| PCT/US2016/052144 WO2017049091A1 (en) | 2015-09-16 | 2016-09-16 | Dna binding agents with a minor groove binding tail |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018527372A JP2018527372A (ja) | 2018-09-20 |
| JP2018527372A5 true JP2018527372A5 (enExample) | 2019-10-24 |
| JP6966428B2 JP6966428B2 (ja) | 2021-11-17 |
Family
ID=58289623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513780A Active JP6966428B2 (ja) | 2015-09-16 | 2016-09-16 | 副溝結合テイルを有するｄｎａ結合物質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10358439B2 (enExample) |
| EP (1) | EP3350145B1 (enExample) |
| JP (1) | JP6966428B2 (enExample) |
| CN (1) | CN108368006B (enExample) |
| AU (1) | AU2016323777B2 (enExample) |
| PL (1) | PL3350145T3 (enExample) |
| WO (1) | WO2017049091A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4433039A4 (en) * | 2021-11-17 | 2025-10-29 | Univ Texas | WATER-SOLUBLE SALTS OF DNA-BINDING AGENTS |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4288608A (en) | 1978-06-01 | 1981-09-08 | Research Corporation | Synthesis of anthracyclines |
| US4196127A (en) | 1978-06-01 | 1980-04-01 | Research Corporation | Anthracyclines |
| ZA814722B (en) * | 1980-07-18 | 1982-07-28 | Hoffmann La Roche | Novel anthracycline glycosides |
| CA1174669A (en) | 1980-07-18 | 1984-09-18 | Michael J. Broadhurst | Anthracycline glycosides |
| EP0971716A1 (en) * | 1996-03-22 | 2000-01-19 | Waldemar Priebe | Bis-anthracyclines with high activity against doxorubicin resistant tumors |
| GB9812937D0 (en) * | 1998-06-16 | 1998-08-12 | Btg Int Ltd | Compounds |
| EP1165578B1 (en) * | 1999-03-19 | 2012-02-22 | Waldemar Priebe | Methods and compositions for the manufacture of c-3' and c-4' anthracycline antibiotics |
| AU2003217782A1 (en) * | 2002-02-27 | 2003-09-09 | The Government Of The United States Of America, Representated By The Secretary, Deparment Of Health | Dna-binding polyamide drug conjugates |
| AU2003302676A1 (en) * | 2002-12-03 | 2004-06-23 | Blanchette Rockefeller Neurosciences Institute | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
| SE0401066D0 (sv) * | 2004-04-22 | 2004-04-22 | Stefan Sjoeberg | Chemical Derivatives |
| PL380561A1 (pl) | 2006-09-05 | 2008-03-17 | Szeja Wiesław Prochem Szeja | Sposób otrzymywania pochodnych antracyklin |
| WO2010104585A1 (en) * | 2009-03-12 | 2010-09-16 | Luitpold Pharmaceuticals, Inc. | Gaba-linked anthracycline-lipid conjugates |
-
2016
- 2016-09-16 US US15/759,884 patent/US10358439B2/en active Active
- 2016-09-16 PL PL16847389T patent/PL3350145T3/pl unknown
- 2016-09-16 JP JP2018513780A patent/JP6966428B2/ja active Active
- 2016-09-16 AU AU2016323777A patent/AU2016323777B2/en not_active Ceased
- 2016-09-16 EP EP16847389.0A patent/EP3350145B1/en active Active
- 2016-09-16 CN CN201680066385.9A patent/CN108368006B/zh active Active
- 2016-09-16 WO PCT/US2016/052144 patent/WO2017049091A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| RU2014153800A (ru) | Соединения 5-азаиндазола и способы их применения | |
| JP2019519503A5 (enExample) | ||
| RU2014106966A (ru) | Пиразоло[3,4-с]пиридины и способы их применения | |
| JP2020508310A5 (enExample) | ||
| JP2015520753A5 (enExample) | ||
| RS52274B2 (sr) | Jedinjenje diarilhidantoina | |
| JP2013535437A5 (enExample) | ||
| JP2010524957A5 (enExample) | ||
| JP2018513832A5 (enExample) | ||
| JPWO2014157444A1 (ja) | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| WO2016014390A1 (en) | Compositions and methods for mek inhibitor combination therapy in the treatment of cancer | |
| JP2014532751A5 (enExample) | ||
| RU2015114967A (ru) | Производные ингенола, применяемые для лечения рака | |
| CN103965175B (zh) | 4‑(取代苯氨基)喹唑啉类化合物、其制备方法及应用 | |
| RU2010150964A (ru) | Произведенные из свр501 агенты и способы на их основе для ингибирования остановки клеточного цикла g2 и сенсибилизации клеток к повреждающим днк агентам | |
| JP2020518649A5 (enExample) | ||
| RU2004135307A (ru) | Производное эпотилона для лечения гепатомы и других раковых заболеваний | |
| JP2013525290A5 (enExample) | ||
| RU2016116915A (ru) | Комбинация | |
| JP2010500971A5 (enExample) | ||
| RU2016137761A (ru) | Оксепан-2-ил-пиразол-4-ил-гетероциклил-карбоксамиды и способы их применения | |
| RU2010120810A (ru) | Гидратированные кристаллические сложные эфиры камптотецина для лечения рака | |
| ES2286280T3 (es) | Utilizacion de sustancias activas con un efecto agonista de receptores nu de opiodes y con un efecto antagonista de receptores de opiodes, como medicamentos combinados para el tratamiento de un cancer. | |
| JP2011514356A5 (enExample) |